Halozyme dips after ViroPharma ends subcutaneous Cinryze study
This article was originally published in Scrip
Halozyme Therapeutics closed down 14% at $7.32 per share on 1 August after ViroPharma ended a Phase II clinical trial for a subcutaneous formulation of Cinryze that contains Halozyme's recombinant human hyaluronidase (rHuPH20) enzyme after several patients developed non-neutralizing anti-rHuPH20 antibodies.
You may also be interested in...
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.